AU2001252406A1 - Pharmaceutical compositions comprising proton pump inhibitors and gastrin/cholecystokinin receptor ligands - Google Patents

Pharmaceutical compositions comprising proton pump inhibitors and gastrin/cholecystokinin receptor ligands

Info

Publication number
AU2001252406A1
AU2001252406A1 AU2001252406A AU5240601A AU2001252406A1 AU 2001252406 A1 AU2001252406 A1 AU 2001252406A1 AU 2001252406 A AU2001252406 A AU 2001252406A AU 5240601 A AU5240601 A AU 5240601A AU 2001252406 A1 AU2001252406 A1 AU 2001252406A1
Authority
AU
Australia
Prior art keywords
gastrin
pharmaceutical compositions
proton pump
receptor ligands
pump inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001252406A
Inventor
Luc Joseph Andries
James Whyte Black
Robert Antony David Hull
Sarkis Barret Kalindjian
Jean Louis Mesens
Nigel Paul Shankley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
James Black Foundation Ltd
Original Assignee
Janssen Pharmaceutica NV
James Black Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV, James Black Foundation Ltd filed Critical Janssen Pharmaceutica NV
Publication of AU2001252406A1 publication Critical patent/AU2001252406A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
AU2001252406A 2000-05-08 2001-05-04 Pharmaceutical compositions comprising proton pump inhibitors and gastrin/cholecystokinin receptor ligands Abandoned AU2001252406A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0011098.1A GB0011098D0 (en) 2000-05-08 2000-05-08 Pharmaceutical compositions comprising protpn pump inhibitors and gastrin/cholecystokinin receptor ligands
GB0011098 2000-05-08
PCT/GB2001/001963 WO2001085167A1 (en) 2000-05-08 2001-05-04 Pharmaceutical compositions comprising proton pump inhibitors and gastrin/cholecystokinin receptor ligands

Publications (1)

Publication Number Publication Date
AU2001252406A1 true AU2001252406A1 (en) 2001-11-20

Family

ID=9891196

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001252406A Abandoned AU2001252406A1 (en) 2000-05-08 2001-05-04 Pharmaceutical compositions comprising proton pump inhibitors and gastrin/cholecystokinin receptor ligands

Country Status (4)

Country Link
US (1) US20030195240A1 (en)
AU (1) AU2001252406A1 (en)
GB (2) GB0011098D0 (en)
WO (1) WO2001085167A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
US7211590B2 (en) 2002-08-01 2007-05-01 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
WO2005080367A1 (en) * 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
AU2006277786B2 (en) 2005-08-09 2012-09-06 Asterand Uk Acquisition Limited EP2 receptor agonists
US7863330B2 (en) 2006-06-14 2011-01-04 Rottapharm S.P.A. Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders
UY30892A1 (en) * 2007-02-07 2008-09-02 Smithkline Beckman Corp AKT ACTIVITY INHIBITORS
ME03072B (en) 2007-09-10 2019-01-20 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt
WO2009049112A1 (en) * 2007-10-10 2009-04-16 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
EP4242206A1 (en) * 2009-01-30 2023-09-13 Novartis AG Crystalline n-{(1-s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
JP5833011B2 (en) 2009-10-14 2015-12-16 ヤンセン ファーマシューティカ エヌ．ベー． Process for preparing compounds useful as inhibitors of SGLT2
DK2568988T3 (en) 2010-05-11 2016-08-22 Janssen Pharmaceutica Nv Pharmaceutical formulations comprising 1- (BETA-D-glucopyranosyl) -2-THIENYLMETHYLBENZEN derivatives as inhibitors of SGLT
MX2012014273A (en) 2010-06-07 2013-03-22 Novomedix Llc Furanyl compounds and the use thereof.
ES2586846T3 (en) 2011-04-13 2016-10-19 Janssen Pharmaceutica, N.V. Process of preparation of compounds useful as SGLT2 inhibitors
US9035044B2 (en) 2011-05-09 2015-05-19 Janssen Pharmaceutica Nv L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
JP6616790B2 (en) 2014-06-27 2019-12-04 ノグラ ファーマ リミテッド Aryl receptor modulators and methods of making and using the same
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204118A (en) * 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
WO1993012817A1 (en) * 1991-12-20 1993-07-08 Warner-Lambert Company Therapeutic combinations useful in the treatment of gastroesophageal reflux disease
AU758955C (en) * 1998-05-15 2004-09-30 Cancer Advances, Inc. Method for the treatment of gastroesophageal reflux disease
CN1325385A (en) * 1998-11-09 2001-12-05 詹姆斯·布莱克基金有限公司 Gastrin and cholecystokinin receptor ligands
US7365047B1 (en) * 1999-09-28 2008-04-29 The Regents Of The University Of California Use of pentagastrin to inhibit gastric acid secretion or as a diuretic

Also Published As

Publication number Publication date
GB0011098D0 (en) 2000-06-28
GB2379387B (en) 2004-10-06
WO2001085167A1 (en) 2001-11-15
GB2379387A (en) 2003-03-12
US20030195240A1 (en) 2003-10-16
GB0225706D0 (en) 2002-12-11

Similar Documents

Publication Publication Date Title
AU2001252406A1 (en) Pharmaceutical compositions comprising proton pump inhibitors and gastrin/cholecystokinin receptor ligands
PL350729A1 (en) Pharmaceutical composition containing proton pump inhibitors
IL135886A0 (en) Topical compositions for nsai drug delivery
AU6000900A (en) Carbazole derivatives and their use as neuropeptide y5 receptor ligands
AU2791599A (en) Extended release dosage form
AU2997500A (en) Single dose delivery device
AU2001296908A1 (en) Proton pump inhibitor formulation
AU2001252407A1 (en) Gastrin and cholecystokinin receptor ligands (ii)
HU0001561D0 (en) Pump dispenser
IL150062A0 (en) Proton pump inhibitors
AU2001252413A1 (en) Gastrin and cholecystokinin receptor ligands (iii)
AU4594200A (en) Pharmaceutical combination of neurokinin receptor antagonist and proton pump inhibitor
AU2001254940A1 (en) Gastrin and cholecystokinin receptor ligands (iv)
AU6913100A (en) Notch receptor ligands and uses thereof
IL156372A0 (en) Carbazole derivatives and pharmaceutical compositions containing the same
GB9909154D0 (en) Pharmaceutical formulation
AU2001244854A1 (en) Local drug delivery
GB9926251D0 (en) Pharmaceutical formulation
AU5063600A (en) Flagellin peptides and receptors
PL350899A1 (en) Pharmaceutical composition based on polyaromatic compounds
AU2001232068A1 (en) Delivery capsules
SI1156806T1 (en) Pharmaceutical composition containing proton pump inhibitors
AU143244S (en) Fuel dispenser interface
AUPQ070099A0 (en) Pharmaceutical agents
AU5980000A (en) Pumping device for several fuels